27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- At the start of March, BridgeBio Pharma Inc (NASDAQ: BBIO) won approval for its first drug, fosdenopterin, for sporadic cases of molybdenum cofactor deficiency type A.
- In the middle of March, it announced positive proof-of-concept data for encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1).
- Today, the company is wrapping up the busy month with global collaboration and licensing agreement with Helsinn Group to develop and commercialize infigratinib.
- The agreement covers oncology and all other indications except for skeletal dysplasias (including achondroplasia).
- Infigratinib is an orally administered ATP-competitive tyrosine kinase inhibitor designed to inhibit FGFR.
- Under the terms of the Agreement, BridgeBio will retain all rights to infigratinib in skeletal dysplasia, including achondroplasia.
- Subject to FDA approval, BridgeBio Pharma's affiliate QED Therapeutics and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. on a 50:50 basis.
- Under the Agreement, BridgeBio will be eligible to receive more than $2 billion in upfront, regulatory and commercial milestones, as well as tiered royalties on adjusted net sales from Helsinn Group.
- Helsinn will have exclusive commercialization rights and lead commercialization for infigratinib in non-skeletal dysplasia indications outside of the U.S., excluding China, Hong Kong, and Macau, covered under LianBio collaboration.
- Price Action: BBIO shares are up 2.54% at $60.62 in market trading hours on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!